These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 29079457)

  • 21. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
    Sahebi F; Garderet L; Kanate AS; Eikema DJ; Knelange NS; Alvelo OFD; Koc Y; Blaise D; Bashir Q; Moraleda JM; Dreger P; Sanchez JF; Ciurea S; Schouten H; Shah NN; Verbeek M; Rösler W; Diez-Martin JL; Schoenland S; D'Souza A; Kröger N; Hari P
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):335-342. PubMed ID: 30243581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
    Patriarca F; Bruno B; Einsele H; Spina F; Giaccone L; Montefusco V; Isola M; Nozzoli C; Nozza A; Morabito F; Corradini P; Fanin R
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):406-409. PubMed ID: 29032267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
    Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
    Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
    Pemmaraju N; Tanaka MF; Ravandi F; Lin H; Baladandayuthapani V; Rondon G; Giralt SA; Chen J; Pierce S; Cortes J; Kantarjian H; Champlin RE; De Lima M; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):485-92. PubMed ID: 23769669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
    Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
    Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Factors for Postrelapse Survival after ex Vivo CD34
    Gomez-Arteaga A; Shah GL; Baser RE; Scordo M; Ruiz JD; Bryant A; Dahi PB; Ghosh A; Lahoud OB; Landau HJ; Landgren O; Shaffer BC; Smith EL; Koehne G; Perales MA; Giralt SA; Chung DJ
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2040-2046. PubMed ID: 32712326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
    Michallet M; Sobh M; El-Cheikh J; Morisset S; Sirvent A; Reman O; Cornillon J; Tabrizi R; Milpied N; Harousseau JL; Labussière H; Nicolini FE; Attal M; Moreau P; Mohty M; Blaise D; Avet-Loiseau H
    Exp Hematol; 2013 Dec; 41(12):1008-15. PubMed ID: 23994781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
    LeBlanc R; Claveau JS; Ahmad I; Delisle JS; Bambace N; Bernard L; Cohen S; Kiss T; Lachance S; Landais S; Roy DC; Sauvageau G; Roy J
    Clin Transplant; 2020 Dec; 34(12):e14099. PubMed ID: 32981146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
    Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.
    Badar T; Epperla N; Szabo A; Borson S; Vaughn J; George G; Saini N; Shah AR; Patel RD; Ahmed S; Shah NN; Cashen AF; Hamadani M; Fenske TS
    Blood Adv; 2020 Jan; 4(1):47-54. PubMed ID: 31899797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
    Wei M; Xie C; Huang J; Liu Q; Lai Y
    Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
    Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
    Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
    Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
    Iacobelli S; de Wreede LC; Schönland S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N; Gahrton G;
    Bone Marrow Transplant; 2015 Apr; 50(4):505-10. PubMed ID: 25621805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.